Outlook Therapeutics (OTLK) Total Debt (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Total Debt of $21.0 million for Q1 2026, down 36.54% year-over-year from $33.0 million in Q1 2025, and down 42.8% quarter-over-quarter from $36.7 million in Q4 2025.
Outlook Therapeutics (OTLK) Total Debt (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Total Debt for 12 consecutive years, with $21.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt fell 36.54% year-over-year to $21.0 million; the TTM figure through Mar 2026 stood at $21.0 million (down 36.54% YoY), while the FY2025 annual figure was $29.9 million, up 1.72% from the prior year.
- Total Debt retreated to $21.0 million in Q1 2026 per OTLK's latest filing, from $36.7 million in the prior quarter.
- Across five years, Total Debt topped out at $44.7 million in Q1 2024 and bottomed at $10.5 million in Q2 2022.
- Historically, Total Debt has averaged $29.8 million across 5 years, with a median of $31.8 million in 2023.
- Annual changes were most pronounced in 2023 — Total Debt surged 232.08% — and 2026, when it tumbled 36.54%.
- Outlook Therapeutics' Total Debt stood at $31.8 million in 2022, then advanced by 14.85% to $36.5 million in 2023, then declined by 15.87% to $30.7 million in 2024, then rose by 19.24% to $36.7 million in 2025, then slumped by 42.8% to $21.0 million in 2026.
- Business Quant data shows OTLK's Total Debt at $21.0 million in Q1 2026, $36.7 million in Q4 2025, and $29.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 9.34 Bn |
| 10 | Outlook Therapeutics | 93.45 Mn | 82.21 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.97 Mn |
| Dec 31, 2025 | 36.66 Mn |
| Sep 30, 2025 | 29.95 Mn |
| Jun 30, 2025 | 34.44 Mn |
| Mar 31, 2025 | 33.05 Mn |
| Dec 31, 2024 | 30.74 Mn |
| Sep 30, 2024 | 29.44 Mn |
| Jun 30, 2024 | 32.43 Mn |
| Mar 31, 2024 | 44.75 Mn |
| Dec 31, 2023 | 36.54 Mn |
| Sep 30, 2023 | 35.55 Mn |
| Jun 30, 2023 | 34.73 Mn |
| Mar 31, 2023 | 31.82 Mn |
| Dec 31, 2022 | 31.82 Mn |
| Sep 30, 2022 | 10.92 Mn |
| Jun 30, 2022 | 10.46 Mn |
| Mar 31, 2022 | 22.78 Mn |
| Dec 31, 2021 | 22.32 Mn |
| Sep 30, 2021 | 11.79 Mn |
| Jun 30, 2021 | 11.55 Mn |